Results 181 to 190 of about 90,630 (268)
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou +12 more
wiley +1 more source
Impact of Near-Positivity Violations on IPTW-Estimated Marginal Structural Survival Models With Time-Dependent Confounding. [PDF]
Spreafico M.
europepmc +1 more source
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich +5 more
wiley +1 more source
Association between going out for work and self-rated health of rural residents: a longitudinal study in Ningxia, China. [PDF]
Ma X +7 more
europepmc +1 more source
ABSTRACT As environmental pressures and corporate social responsibility demands intensify, organizations face growing pressure to adopt adaptive, sustainability‐oriented strategies. This challenge is especially relevant in globally significant industries such as wine production, which is economically and culturally vital in countries like Italy.
Leonardo Agnusdei +2 more
wiley +1 more source
Using single-step genome-wide association analyses to compare predicted negative energy balance and a novel energy deficiency score in early-lactation Holstein cows. [PDF]
Hu H +8 more
europepmc +1 more source
The role of investment for poverty alleviation in Yogyakarta: Evidence from logit regression
Suripto Suripto +4 more
openalex +1 more source

